{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTLA-4+Antibody&page=2",
    "query": {
      "intervention": "CTLA-4 Antibody",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 365,
    "total_pages": 37,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTLA-4+Antibody&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CTLA-4+Antibody&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T13:19:45.923Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05896839",
      "title": "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8",
        "Metastatic Basal Cell Carcinoma",
        "Metastatic Carcinoma in the Skin",
        "Metastatic Melanoma",
        "Metastatic Merkel Cell Carcinoma",
        "Metastatic Skin Squamous Cell Carcinoma",
        "Unresectable Basal Cell Carcinoma",
        "Unresectable Melanoma",
        "Unresectable Merkel Cell Carcinoma",
        "Unresectable Skin Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Kidney Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2024-07-24",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-09-30T13:19:45.923Z",
      "location_count": 26,
      "location_summary": "La Jolla, California • Los Angeles, California • Washington D.C., District of Columbia + 18 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05896839"
    },
    {
      "nct_id": "NCT04380805",
      "title": "A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Cervical Cancer",
        "Metastatic Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "AK104",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Akeso",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2020-07-15",
      "completion_date": "2023-01-31",
      "has_results": false,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-09-30T13:19:45.923Z",
      "location_count": 19,
      "location_summary": "Newport Beach, California • Miami, Florida • Plantation, Florida + 16 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04380805"
    },
    {
      "nct_id": "NCT04462406",
      "title": "Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Melanoma",
        "Clinical Stage III Cutaneous Melanoma AJCC v8",
        "Clinical Stage IV Cutaneous Melanoma AJCC v8",
        "Melanoma of Unknown Primary",
        "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IIID Cutaneous Melanoma AJCC v8",
        "Pathologic Stage IV Cutaneous Melanoma AJCC v8",
        "Unresectable Acral Lentiginous Melanoma",
        "Unresectable Melanoma",
        "Unresectable Mucosal Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Patient Observation",
          "type": "OTHER"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2021-02-09",
      "completion_date": "2030-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-09-30T13:19:45.923Z",
      "location_count": 482,
      "location_summary": "Fairhope, Alabama • Mobile, Alabama • Fairbanks, Alaska + 330 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04462406"
    },
    {
      "nct_id": "NCT03604991",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Clinical Stage II Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage III Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Esophageal Adenocarcinoma",
        "Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 278,
      "start_date": "2019-05-03",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-09-30T13:19:45.923Z",
      "location_count": 488,
      "location_summary": "Anchorage, Alaska • Phoenix, Arizona • Fort Smith, Arkansas + 341 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03604991"
    },
    {
      "nct_id": "NCT03606967",
      "title": "Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Invasive Breast Carcinoma",
        "Metastatic Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Gemcitabine Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Personalized Synthetic Long Peptide Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Poly ICLC",
          "type": "DRUG"
        },
        {
          "name": "Sacituzumab Govitecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tremelimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2021-04-13",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-09-30T13:19:45.923Z",
      "location_count": 30,
      "location_summary": "Orange, California • Sacramento, California • Aurora, Colorado + 22 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03606967"
    },
    {
      "nct_id": "NCT01116427",
      "title": "A Cooperative Clinical Study of Abatacept in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "abatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 65,
      "start_date": "2010-09",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2016-09-15",
      "last_synced_at": "2026-09-30T13:19:45.923Z",
      "location_count": 20,
      "location_summary": "Phonix, Arizona • Berkeley, California • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Phonix",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01116427"
    },
    {
      "nct_id": "NCT01750983",
      "title": "Ipilimumab and Lenalidomide in Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancers"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2013-03",
      "completion_date": "2019-02-21",
      "has_results": false,
      "last_update_posted_date": "2019-02-25",
      "last_synced_at": "2026-09-30T13:19:45.923Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01750983"
    },
    {
      "nct_id": "NCT04551430",
      "title": "Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Soft-tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2021-01-05",
      "completion_date": "2029-02-01",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-09-30T13:19:45.923Z",
      "location_count": 4,
      "location_summary": "Stanford, California • Aurora, Colorado • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04551430"
    },
    {
      "nct_id": "NCT01729806",
      "title": "Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "CD20 Positive",
        "Recurrent B-Cell Non-Hodgkin Lymphoma",
        "Refractory B-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2012-11-19",
      "completion_date": "2018-03-30",
      "has_results": false,
      "last_update_posted_date": "2018-04-11",
      "last_synced_at": "2026-09-30T13:19:45.923Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "South Pasadena",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01729806"
    },
    {
      "nct_id": "NCT02339571",
      "title": "A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Stage III Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Elastography",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sargramostim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2015-11-23",
      "completion_date": "2033-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-09-30T13:19:45.923Z",
      "location_count": 763,
      "location_summary": "Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 494 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02339571"
    }
  ]
}